Complete radiological response of hepatic metastases from bladder cancer following whole-liver low-dose radiotherapy with simultaneous integrated boost combined with chemoimmunotherapy: a case report
Background Urothelial carcinoma with neuroendocrine differentiation is a rare, yet highly aggressive histological subtype of bladder cancer, characterized by rapid disease progression, poor prognosis, and a tendency to metastasize, with the liver being a common metastatic site. Current treatments involving chemotherapy and immunotherapy have limitations, including poor patient tolerability and the rapid development of drug resistance, particularly in patients exhibiting low PD-L1 expression and those who have failed multiple lines of therapy. Increasing evidence supports the use of low-dose radiotherapy (LDRT) as an immunomodulatory approach that can overcome drug resistance in many patients. Case presentation Herein, we report the case of a 54-year-old male patient with urothelial carcinoma exhibiting partial neuroendocrine differentiation and extensive liver metastases. PD-L1 testing revealed a combined positive score of 1. The patient had developed resistance following first-line chemotherapy and second-line chemoimmunotherapy. As a third-line treatment, he received whole-liver LDRT (WL-LDRT: 5 Gy in 10 fractions), with a simultaneous integrated boost to selected lesions, combined with immunotherapy and chemotherapy. One month post-treatment, imaging demonstrated that the patient had shown a partial response to treatment, athree months later, all the liver metastases were disappeared. Notably, the patient achieved progression-free survival exceeding 9 months. Conclusion To the best of our knowledge, this is the first case report of a patient with extensive liver metastases from bladder cancer who achieved complete radiological response of the hepatic metastases after overcoming resistance to both chemotherapy and immunotherapy with a combination of WL-LDRT and simultaneous integrated boost. This case highlights a novel and potentially safe salvage strategy for treating similar cases of chemotherapy- and immunotherapy-refractory metastatic bladder cancer, which could help improve the clinical outcomes of patients with this rare but highly aggressive cancer.
Authors
- 喻雄杰
- Fengjun Cao (ORCID: https://orcid.org/0000-0002-0494-3474)
- Liguo Gao
- Changmin Han
Institutions
- Hubei University of Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fonc.2026.1965942
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00